72.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$73.00
Offen:
$72.89
24-Stunden-Volumen:
3.97M
Relative Volume:
0.75
Marktkapitalisierung:
$112.19B
Einnahmen:
$54.98B
Nettoeinkommen (Verlust:
$7.77B
KGV:
29.06
EPS:
2.49
Netto-Cashflow:
$9.14B
1W Leistung:
+2.09%
1M Leistung:
+0.36%
6M Leistung:
+7.14%
1J Leistung:
-9.92%
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
72.35 | 219.73B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
2025-02-13 | Hochstufung | UBS | Neutral → Buy |
2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
2024-11-20 | Hochstufung | UBS | Sell → Neutral |
2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
2024-05-30 | Eingeleitet | Goldman | Buy |
2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
2024-01-16 | Fortgesetzt | UBS | Sell |
2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
2023-12-18 | Eingeleitet | HSBC Securities | Buy |
2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-07-12 | Hochstufung | UBS | Neutral → Buy |
2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-08-29 | Hochstufung | Argus | Hold → Buy |
2022-06-14 | Herabstufung | UBS | Buy → Neutral |
2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
2021-04-12 | Herabstufung | Argus | Buy → Hold |
2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
2021-02-25 | Hochstufung | UBS | Neutral → Buy |
2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-11-30 | Hochstufung | UBS | Sell → Neutral |
2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
2019-10-25 | Hochstufung | Liberum | Hold → Buy |
2019-04-02 | Herabstufung | UBS | Neutral → Sell |
2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
2018-12-11 | Fortgesetzt | Jefferies | Hold |
2018-10-09 | Eingeleitet | Guggenheim | Buy |
2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
2018-02-05 | Bestätigt | Bernstein | Outperform |
2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca (AZN) Veteran Joins Perrigo Leadership Team | AZN St - GuruFocus
Hydrogel-based Drug Delivery System Market Top Companies Study - openPR.com
Transcript : AstraZeneca PLC Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 - marketscreener.com
AZN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm - ACCESS Newswire
AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment - Yahoo
M42 Partners with AstraZeneca, Sophia Genetics for Liquid Biopsy Testing in UAE - marketscreener.com
AstraZeneca: Enhertu promising against breast cancer - marketscreener.com
AstraZeneca (AZN) Reports Promising Phase 3 Results for Enhertu and Perjeta Combo - GuruFocus
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Nasdaq
AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer (AZN:NASDAQ) - Seeking Alpha
AstraZeneca (AZN) Considered for Potential Pharma Collaborations | AZN Stock News - GuruFocus
astrazeneca announces total voting rights update for may 2025 By Investing.com - Investing.com India
astrazeneca reports block listing interim review for share schemes - Investing.com
astrazeneca reports block listing interim review for share schemes By Investing.com - Investing.com UK
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO - Benzinga
AstraZeneca (AZN) Highlights Encouraging Enhertu Results in Breast Cancer Trial | AZN Stock News - GuruFocus
Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study - Bloomberg
AstraZeneca (AZN) Highlights Success in Breast Cancer Trial with Camizestrant | AZN Stock News - GuruFocus
AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com
AstraZeneca: camizestrant effective in breast cancer - marketscreener.com
Astra Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg
AstraZeneca - Britannica
AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit
ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6 - insights.citeline.com
PRESS DIGEST- Financial TimesJune 2 - marketscreener.com
AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials - GuruFocus
AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus
AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boo - GuruFocus
AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive
AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com
AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News
AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters
Danaher Partners With AstraZeneca to Support Precision Medicine - Yahoo Finance
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com
Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com
AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance
AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360
Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha
Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
Responsible care and use of animals in research - AstraZeneca
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):